Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Time to treatment of uveal melanoma in the United Kingdom

Abstract

Purpose To measure delay before treatment of uveal melanoma.

Methods A retrospective study was carried out of patients referred for diagnosis and treatment of uveal melanoma at the Liverpool Ocular Oncology Centre (LOOC), a tertiary adult ocular oncology service. Participants were patients with uveal melanoma presenting to an optometrist or general practitioner in the United Kingdom between 1997 and 2000. Main outcome measures were delay at each stage of the referral process according to route of referral and tumour size.

Results Delays greater than 2 weeks occurred (1) between presentation to the optometrist or general practitioner and the ophthalmologist's examination in 50% of patients; (2) between the ophthalmologist's examination and receipt of the referral at the ocular oncology centre in 34%; (3) between receipt of referral at the oncology centre and first assessment at that centre in 16%; and (4) between first assessment at the oncology centre and treatment in 8%. The waiting time for the ophthalmologist's examination was greater if the optometrist referred the patient via the general practitioner instead of directly. The median overall delays between presentation and treatment were 129 days for small tumours, 50 days for medium-sized tumours and 34 days for large tumours.

Conclusions Many patients with uveal melanoma experience long delays before treatment. Patients wait longer to see an ophthalmologist if their tumour is small or if they are referred by the optometrist to the general practitioner instead of directly to the ophthalmologist. Several patients also experience long delays after seeing the ophthalmologist, some having a large tumour by the time of teatment.

References

  1. Scotto J, Fraumeni JF Jr, Lee JAH . Melanomas of the eye and other noncutaneous sites: epidemiologic aspects. J Natl Cancer Inst 1976;56:489–91.

    CAS  Article  Google Scholar 

  2. Damato BE . Ocular tumours: diagnosis and treatment. Oxford: Butterworth-Heinemann, 2000:74–87.

  3. Diener West M, Hawkins BS, Markowitz JA, Schachat AP . A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 1992;110:245–50.

    CAS  Article  Google Scholar 

  4. Holden R, Damato BE . Preventable delays in the treatment of intraocular melanoma in the UK. Eye 1996;10:127–9.

    Article  Google Scholar 

  5. Ah-Fat FG, Damato BE . Delays in the diagnosis of uveal melanoma and effect on treatment. Eye 1998;12:781–2.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Bertil Damato.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Damato, B. Time to treatment of uveal melanoma in the United Kingdom. Eye 15, 155–158 (2001). https://doi.org/10.1038/eye.2001.51

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/eye.2001.51

Keywords

  • Adult
  • Analysis
  • Diagnosis
  • Eye neoplasms
  • Human
  • Melanoma
  • Patients
  • Therapy
  • Time

Search

Quick links